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Abstract
Background: Arthritis is one of the most common manifestations of systemic lupus erythematosus (SLE). Although
typically non-erosive and non-deforming, children with SLE arthritis can have significant morbidity with decreased
quality of life. Our goal was to identify potential clinical and laboratory predictors of arthritis in a cohort of pediatric
patients with SLE.
Methods: We performed a cohort study of incident and prevalent patients with SLE aged ≤ 19 years. In cross
sectional analysis, we compared demographic and clinical characteristics at initial clinic presentation between
patients with arthritis noted at any time during follow-up and those without arthritis. We performed time to event
analysis using Cox proportional hazard ratios to identify predictors of arthritis, clustering for repeated measures.
Results: Forty seven children and adolescents with SLE were followed in the cohort, 91 % female and 68 % Black.
In cross-sectional analyses, presence of malar rash was associated with arthritis. In longitudinal analyses, controlling
for gender and race, increased age (HR: 1.4, 95 % CI: 1.1–1.7), malar rash (HR: 2.1, 95 % CI: 1.1–3.6), and presence of
RNP antibodies (HR: 1.9, 95 % CI: 1.1–3.4) were predictive of arthritis. When controlling for gender, race, and medication
use, anemia (HR: 8.5, 95 % CI: 2.9–24.2) and thrombocytopenia (HR: 6.1, 95 % CI: 2.4–15.6) were associated with
increased risk of arthritis.
Conclusions: We identified markers predictive of arthritis in a longitudinal cohort of children with SLE. The recognition
of these markers may help clinicians identify patients at risk for arthritis before its onset thus improving quality of life in
children with SLE.
Background
Systemic lupus erythematosus (SLE) is a multi-system
autoimmune disease that can present in childhood. Up to
20 % of patients with SLE are diagnosed in the pediatric
population and females are more commonly affected than
males [1].
Arthritis is one the most common manifestations of
SLE in both children and adults and is in fact one of the
criteria used to make the diagnosis of SLE [2–5]. The arth-
ritis of SLE is typically non-erosive and non-deforming
and involves both large and small joints [2].
Studies have shown that although the arthritis in SLE
does not usually cause joint damage, it can be associated
with significant decrease in quality of life in these children
[6, 7]. In a cohort of 98 children with SLE, the presence of
arthritis was associated with significantly worse quality of
life and decreased function [6]. In comparison, other man-
ifestations of SLE, including active lupus nephritis and
renal damage, were not associated with decreased health-
related quality of life. This indicates that although the
arthritis of SLE is typically non-deforming, it is associated
with significant morbidity in this population [6, 7]. Our
goal was to define predictors of arthritis in a longitudinal
cohort of pediatric patients with SLE.
Methods
SLE cohort
Incident and prevalent patients with SLE onset at
age ≤19 years were recruited into this cohort study. These
subjects were seen during their routine clinic visits every
3 months or more frequently if medically indicated. Sub-
jects were recruited from Johns Hopkins University and
the Children’s Hospital of Philadelphia in a longitudinal
study from July 2008 through December 2012. Institutional
review board approval was obtained at both institutions
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and all subjects/families enrolled in the cohort study con-
sented for participation. For prevalent SLE patients, we
performed retrospective chart review to collect clinical and
laboratory data from the time of SLE diagnosis to cohort
entry. All patients met the American College of Rheuma-
tology (ACR) classification criteria for SLE [3–5].
At entry into the cohort, demographic data including
age at visit, age at lupus diagnosis, gender, race, and ethni-
city were collected. At each visit, history and physical
exam data, medication, and laboratory information were
collected. Laboratory data included complete blood count,
erythrocyte sedimentation rate, basic metabolic profile,
urinalysis, spot urine protein to creatinine ratio, comple-
ment levels (C3, C4), and autoantibodies including ANA,
dsDNA, Ro, La, Smith (Sm), and RNP antibodies. The
SLE Disease Activity Index (SLEDAI) and the Systemic
Lupus Activity Measure (SLAM) disease activity measures
were also calculated at each visit [8–12]. The SLEDAI is a
weighted, cumulative index that is grouped into 9 organ
systems. The organ systems include central nervous sys-
tem, vascular, renal, musculoskeletal, serosal, dermal, im-
munologic, constitutional, and hematologic [11]. The
SLAM is used to assess degree of disease activity within
the preceding month and includes clinical manifestations
and 8 laboratory parameters, each weighted [9].
Definition of arthritis
Arthritis was based on the ACR definition in the classifi-
cation criteria for SLE [3, 4]. This includes non-erosive
arthritis involving two or more peripheral joints, charac-
terized by tenderness, swelling, or effusion. To be included
in the analyses, the arthritis must have been documented
by the treating physician and have been present for at least
the two weeks preceding the clinic visit.
Statistical analysis
We performed t-test for comparison of means and chi-2
analyses for comparison of groups, comparing baseline
clinical and demographic characteristics of patients with-
out arthritis vs. those with arthritis at any time during
cohort follow-up.
In longitudinal analyses, times to event calculations
were used to determine the association between clinical,
laboratory, and disease activity variables with arthritis.
Time at risk was calculated using date of SLE diagnosis as
the start date and either end of follow-up or December 31,
2012, the last date of data collected, as the end date. Fail-
ure, or the event of interest, was defined as the develop-
ment of arthritis.
Cox proportional hazard ratios were used to determine
predictors of arthritis. Both univariate and multivariate
analyses were performed. In multivariate analyses, we con-
trolled for potential confounding of race and gender. When
analyzing the potential relationship between hematologic
disease and arthritis, we controlled for race, gender, and
immunosuppression use. Clustering by identification num-
ber was used to account for multiple measures within the
same patient. If a subject presented with arthritis at the ini-
tial diagnosis of SLE, that visit was excluded from the lon-
gitudinal analyses since no prior data were available.
Demographic characteristics included age, gender and
race. Laboratory data used in these analyses included auto-
antibodies including dsDNA, Ro, La, Smith, RNP, serum
complement levels, hemoglobin, white blood cell count,
platelet count, sedimentation rate, and C-reactive protein.
Laboratory variables were defined as abnormal if they were
noted to be outside of the recommended ranges. dsDNA
titers were noted as either positive or negative; C3 was de-
fined as low if <79 milligrams (mg) /deciliter (dl); C4 was
low if < 12 mg/dl; low hemoglobin was defined as <11
grams (g)/dl, leukopenia as leukocyte count of <3000/
mm3, thrombocytopenia as fewer than 100,000 platelets,
sedimentation rate elevated if > 20 mm/h, and C-reactive
protein was elevated if >0.5 mg/dl. Mean SLEDAI and






N = 25 N = 22
Age, years (SD) 12.5 (3.5) 11.8 (4.2) 0.6
Gender, n (%) F 22 (88) 20 (90) 0.9
Race, % AA 17 (68) 14 (64) 0.3
ANA, n (%) positive 25 (100) 22 (100) -
dsDNA, n (%) positive 21 (84) 15 (68) 0.4
Ro, n (%) positive 7/18 (39) 1/6 (16) 0.4
La, n (%) positive 5/18 (28) 0/6 (0) 0.1
RNP, n (%) positive 9/20 (45) 5/9 (55) 0.5
Sm, n (%) positive 11/20 (55) 4/8 (50) 0.4
Low C3, n (%) 21 (84) 13 (59) 0.8
Low C4, n (%) 15 (60) 13 (59) 0.8
Elevated CRP, n (%) 13 (52) 2 (9) 0.02
Elevated ESR, n (%) 18 (72) 13 (59) 0.4
Renal disorder, n (%) 16 (64) 9 (41) 0.8
Hematologic disorder,
n (%)
11 (44) 4 (18) 0.2
Fever, n (%) 4 (16) 4 (18) 0.4
Malar rash, n (%) 4 (16) 11 (50) 0.02
Mucosal ulcerations,
n (%)
2 (8) 2 (9) 0.6
Alopecia, n (%) 22 (88) 2 (9) 0.007
Mean SLEDAI 12.8 ± 14.2 10.7 ± 11.7 0.6
Mean SLAM 5.1 ± 3.6 5.4 ± 3.1 0.6
Laboratory values, SLEDAI, and SLAM scores were taken from the first
presentation to the clinic. Renal, hematologic, skin, and integument
involvement were defined as present if noted at any time during
longitudinal follow-up
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SLAM disease activity scores were also included in the
analyses. Missing data were imputed based on prior la-
boratory results. Other clinical findings of SLE were
also included in the analyses including evidence of mu-
cocutaneous involvement (malar rash, oral ulcers, alo-
pecia), hematologic abnormalities, and kidney disease
(defined as any type of lupus nephritis on kidney bi-
opsy). There were too few patients with discoid rash
alone (n = 1), neurologic (n = 1), or serosal involvement
(n = 2) to include these SLE findings in the analyses.
Immunosuppressive medication use at the visit prior to
the development of arthritis was also included in the
analyses. Data were analyzed using STATA, version 11
(Stata Corporation, College Station, TX). P-values less
than 0.05 were considered significant.
Results
47 pediatric patients with SLE were recruited into this
cohort study with 126.5 person-years of longitudinal
data. 90 % of patients were enrolled in the cohort at the
time of initial diagnosis of SLE. In the remaining 10 % of
subjects, data from the time of SLE diagnosis to time of
cohort enrollment were collected through chart review.
Demographic and clinical characteristics of subjects at
the time of initial SLE diagnosis are shown in Table 1.
Patients were divided into two groups: those without
arthritis and those with arthritis at any time during lon-
gitudinal follow-up. There was no significant difference
in baseline characteristics, autoantibody status, or dis-
ease activity scores between these groups. Malar rash
was noted at the first clinic visit more often in patients
who subsequently developed arthritis (50 % in those with
arthritis vs. 16 % without arthritis, p = 0.02).
In this cohort, 10/47 (21 %) had arthritis noted at mul-
tiple non-consecutive clinic visits for a total of 60 epi-
sodes of arthritis during longitudinal follow-up. 2/10
patients had arthritis at the initial diagnosis of SLE; no
patients had only a single episode of arthritis. As show
in Fig. 1, the majority of patients presented with arthritis
within two years from time of SLE diagnosis. The most
common joints involved included the hand (8/10), wrist
(6/10), knee (4/10), and elbow (3/10). None of the pa-
tients had radiologic evaluation.
We next sought to identify potential predictors of
arthritis over time in the cohort (Table 2). In univariate
analyses, increasing age was associated with arthritis
(Hazard Ratio (HR): 1.3, 95 % Confidence Interval (CI):
1.1–1.6). Patients with antibodies to RNP were at in-
creased risk of developing arthritis (HR: 2.1, 95 % CI:
1.2–3.5). Arthritis was less likely in patients of Black race
compared to Caucasians.
When controlling for race and gender, increasing age
remained a significant predictor of arthritis (HR: 1.4,
95 % CI: 1.1–1.7). The presence of RNP antibodies also
remained predictive of arthritis. Those with a malar rash
had a two-fold increased risk of arthritis compared to
patients with no skin involvement (HR: 2.1, 95 % CI:
1.1–3.6). Anemia was predictive of arthritis, even after
controlling for use of immune suppression, race, and
gender (HR: 8.5, 95 % CI: 2.9–24.2). Patients with thro-
mobocytopenia had a six-fold increased risk of arthritis,
even after controlling for potential confounders (HR:
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Kaplan-Meier survival estimate
Fig. 1 Timeline of Arthritis Development. Arthritis presented in all patients within two years of the diagnosis of SLE
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Non-steroidal anti-inflammatory agents were used as
the initial treatment for arthritis in all of the patients. In
two patients, a steroid tapering dose pack was also used
as treatment for arthritis. Methotrexate was started in
three of the patients at the visit where arthritis was re-
corded. In longitudinal analyses, there was no associ-
ation between development of arthritis and use of
immunosuppressive medication at the visit prior (HR:
0.8, 95 % CI: 0.5–1.4).
Discussion
In this longitudinal study, we found that approximately
20 % of patients had at least one episode of non-
deforming arthritis during follow-up. The majority of
patients presented with arthritis within two years of the
diagnosis of SLE. Older, Caucasian children were at in-
creased risk of developing arthritis. Both the presence of
anti-RNP antibodies and malar rash doubled the risk of
developing arthritis in this cohort. Hematologic abnor-
malities, including anemia and thrombocytopenia, were
predictive of future arthritis.
Joint symptoms, including arthritis and arthralgia, have
been noted in 20-90 % of patients with childhood-onset
SLE [13]. Saketoo et al. classified lupus arthritis into five
categories: 1) SLE arthralgia without inflammatory signs
such as erosions or deformity; 2) non-deforming, non-
erosive inflammatory arthropathy; 3) non-deforming,
erosive arthropathy; 4) mechanically erosive deforming ar-
thropathy; and 5) synovial erosive deforming arthorpathy
[14]. Others such as Ball et al. have divided lupus arthritis
into three broad categories: 1) deforming, non-erosive
arthopathy including Jacoud’s arthropathy; 2) mild deform-
ing arthropathy which includes patient who have obvious
deformity and no erosions; and 3) erosive arthritis [15].
The most common type of lupus arthritis is non-
deforming, non-erosive joint inflammation [15]. This differs
from the arthritis seen in children with juvenile idiopathic
arthritis, which is typically inflammatory and can lead to
significant joint damage and erosions. SLE arthritis most
commonly involves the small joints of the hands and feet as
well as larger joints such as knees, ankles, wrists. Chronic
arthritis, defined as persistence of arthritis for more than
6 weeks, is rare in childhood SLE with a prevalence of
2.6 % [16]. None of the children in our cohort had arthritis
for more than 4 consecutive weeks.
In a cross-sectional analysis of 533 adult patients with
SLE, arthralgias and arthritis were noted in 83 % of the
cohort [17]. When comparing patients with articular in-
volvement vs. without articular involvement, it was
noted that female gender, fevers, oral ulcers, and alope-
cia were more prevalent in the group with articular dis-
ease [17]. In our population, these factors were not
associated with arthritis. In fact, children without arth-
ritis were noted to have a statistically significant increase
in alopecia at initial clinic presentation. These differ-
ences in SLE disease associations with arthritis may be
due to variations between childhood and adult SLE.
In a study of 1,082 Chinese patients with SLE, distinct
clusters of SLE disease were noted [18]. The first cluster
was noted to have relatively benign disease with skin in-
volvement, arthritis, and photosensitivity. The second
group was noted to have serositis, hematologic involve-
ment, and renal disease. The third subset was noted to
have arthritis, hematologic involvement, and renal disease.
Although the latter two groups had similar renal and
hematologic presentations, the group with these manifes-
tations plus arthritis had a significantly better prognosis.
The authors felt that the presence of skin and joint disease
may be associated with improved outcomes in patients
with SLE. It was also noted that the first cluster of pa-
tients, with predominately skin and joint involvement, had









and gender (95 %
Confidence interval)
Age, years 1.3 (1.1–1.6) 1.4 (1.1–1.7)
Male gender 2.9 (0.8–9.7) 1.6a (0.4–6.3)
Black race 0.3 (0.1–0.9) 0.3b (0.1–1.1)
dsDNA 1.5 (0.5–4.3) 1.5 (0.5–4.2)
Ro 0.6 (0.3–1.6) 0.8 (0.3–2.2)
La 1.3 (0.3–5.4) 1.4 (0.3–6.6)
RNP 2.1 (1.2–3.5) 1.9 (1.1–3.4)
Sm 0.6 (0.2–1.8) 0.3 (0.06–1.3)
Low C3 0.6 (0.3–1.1) 0.6 (0.3–1.2)
Low C4 0.7 (0.3–1.6) 0.7 (0.3–1.5)
Elevated CRP 0.9 (0.8–1.1) 0.9 (0.8–1.1)
Elevated ESR 0.5 (0.3–1.1) 0.6 (0.3–1.3)
Renal disorder 1.1 (0.5–2.9) 1.2 (0.4–2.8)
Anemia 8.8 (2.7–28.5) 8.5c (2.9–24.2)
Thrombocytopenia 3.1 (0.8–11.7) 6.1c (2.4–15.6)
Leukopenia 1.1 (0.3–4.5) 0.8c (0.2–2.9)
Fever 1.2 (0.4–3.9) 1.3 (0.3–5.4)
Malar rash 1.8 (0.9–3.2) 2.1 (1.1–3.6)
Mucosal ulcerations 1.6 (0.8–3.1) 1.3 (0.6–2.9)
Alopecia 0.8 (0.4–1.5) 0.8 (0.4–1.5)
Prednisone use 0.4 (0.2–3.6) 0.9 (0.7–3.2)
Immunosuppressive
medication use
0.8 (0.5–1.4) 1.05 (0.6–1.7)
SLEDAI score 1.1 (0.9–1.2) 0.9 (0.8–1.1)
SLAM score 1.1 (0.9–1.3) 1.1 (0.8–1.4)
aControlling for Race only; bControlling for Gender only; cControlling for Race,
Gender, and Immunosuppression use
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relatively benign disease with very few flares. This benign
clinical subset of SLE patients has been reported by other
investigators as well [19, 20].
In this study, we found that children with SLE and
RNP antibodies were at increased risk of developing
arthritis. In a comparison of adult SLE patients with
deforming, non-erosive arthritis, it was noted that there
was association between presence of arthropathy and
anti-dsDNA antibodies [21]. In a separate study of thir-
teen patients with SLE and deforming arthritis, a higher
prevalence of anti-Ro and anti-La antibodies were noted
compared to those without arthritis [22]. We did not
routinely check rheumatoid factor or anti-cyclic citrulli-
nated peptide (CCP) antibodies in this cohort. Other in-
vestigators have noted an increased risk of erosive
arthritis in adult SLE patients who have concomitant
anti-CCP antibodies [21, 23–26].
Anemia and thrombocytopenia were predictors of
arthritis in our cohort. In a study by Cavalcante et al. of
seven pediatric patients with SLE and chronic polyar-
thritis, hematologic involvement was noted in six of the
seven subjects [16]. Thrombocytopenia has been associ-
ated with worse prognosis in adults with SLE [27]. The
presence of thrombocytopenia significantly worsened the
probably of survival over 15 years in a cohort of 389
adults with SLE. It is possible that these hematologic
findings of anemia and thrombocytopenia are surrogates
for worse disease.
Our study has some limitations. We combined all
immunosuppressive medications, including hydroxy-
chloroquine, methotrexate, mycophenolate mofetil, and
cyclophosphamide into one variable because medication
use varied throughout the cohort and differences were
noted in prescribing practice and treatment of SLE be-
tween the two centers. Other disease manifestations may
prompt earlier immune suppression treatment and alter
the expression of arthritis. Additionally, we did not rou-
tinely check antibodies more commonly associated with
chronic arthritis such as rheumatoid factor or anti-CCP
antibodies. Strengths of our study include the longitudinal
data collection with the same treating physician at each
site performing the physical exams.
Conclusions
Identifying risk factors for arthritis is important because
of the negative impact of joint pain on quality of life and
function in these children. In this study, we have shown
that arthritis is relatively common in a cohort of
pediatric patients with SLE. Predictors of arthritis in-
clude increasing age, malar rash, autoantibodies, and
hematologic disorder. The recognition of these potential
predictors may help clinicians identify patients at risk
for arthritis before its onset.
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